This proposal brings together the translational medicine expertise of Dana-Farber Cancer Institute (DFCI) with the clinical research strength of Intergroupe Francophone du Myeloma (IFM) in France and the genomics expertise of the Sanger Institute in the UK to develop a curative strategy for MM. In the proposed international collaborative project, we will initiate the most important clinical trial in MM to date, integrating bortezomib, lenalidomide and dexamethasone with high dose therapy in an effort to pursue cure in MM (Project 1). This trial will provide 1000 MM and normal cell samples from newly diagnosed and uniformly treated patients to comprehensively characterize the MM genome and to define molecular events driving development and progression of MM (Project 2);to identity novel therapeutic targets and agents (Project 3) and biomarkers (Projects 1,2,4);as well as to define the mechanism and clinical implications of genomic instability in MM (Project 4). The ultimate goal of the research projects in this program is to identify oncogenomic changes and their relationship with clinical outcome;and to identify and develop innovative therapies targeting molecular abnormalities in MM. This unique collaborative effort requires significant coordination of effort, integration of strategies, monitoring and oversight of various functions, and communication between investigators at various dispersed sites. The key function of Core A is integration of the research efforts and communication between investigators. Scientific and administrative integration is essential to assure successful interaction between the four Projects, as well as between the laboratory and clinical components within and between projects in this multinational multi-institutional program. Therefore, this central core will provide the link between various projects and successfully co-ordinate the clinical study and the proposed correlative science. To aid in achieving these goals. Core A will: monitor the timely conduct of the clinical study and assure progress in tissue collection, processing and usage to co-ordinate interaction between the clinical and correlative science studies (Specific Aim 1);provide necessary resources, fiscal oversight and administrative support for projects and cores (Specific Aim 2);co-ordinate communication, and exchange of data between investigators at various international sites (Specific Aim 3);facilitate intra-programatic interactions, meetings, travel and Internal and External Advisory Committees (Specific Aim 4).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Bae, J; Prabhala, R; Voskertchian, A et al. (2015) A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia 29:218-29
Hu, Y; Song, W; Cirstea, D et al. (2015) CSNK1?1 mediates malignant plasma cell survival. Leukemia 29:474-82
Moreau, Philippe; Cavo, Michele; Sonneveld, Pieter et al. (2014) Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related J Clin Oncol 32:2173-80
Lu, R; Pal, J; Buon, L et al. (2014) Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. Oncogene 33:1495-505
Anderson, K K; Flora, N; Archie, S et al. (2014) A meta-analysis of ethnic differences in pathways to care at the first episode of psychosis. Acta Psychiatr Scand 130:257-68
Chretien, Marie-Lorraine; Hebraud, Benjamin; Cances-Lauwers, Valérie et al. (2014) Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. Haematologica 99:1236-8
Samur, Mehmet Kemal (2014) RTCGAToolbox: a new tool for exporting TCGA Firehose data. PLoS One 9:e106397
Cottini, Francesca; Hideshima, Teru; Xu, Chunxiao et al. (2014) Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med 20:599-606
Hebraud, B; Leleu, X; Lauwers-Cances, V et al. (2014) Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 28:675-9
Cooke, Susanna L; Shlien, Adam; Marshall, John et al. (2014) Processed pseudogenes acquired somatically during cancer development. Nat Commun 5:3644

Showing the most recent 10 out of 35 publications